A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1698

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Orforglipron
DRUG: Semaglutide

Sponsor

Eli Lilly and Company